High-affinity ligands of the colchicine domain in tubulin based on a structure-guided design.Bueno, O., Estevez Gallego, J., Martins, S., Prota, A.E., Gago, F., Gomez-SanJuan, A., Camarasa, M.J., Barasoain, I., Steinmetz, M.O., Diaz, J.F., Perez-Perez, M.J., Liekens, S., Priego, E.M.
(2018) Sci Rep 8: 4242-4242
- PubMed: 29523799
- DOI: 10.1038/s41598-018-22382-x
- Primary Citation of Related Structures:
- PubMed Abstract:
Microtubule-targeting agents that bind at the colchicine-site of tubulin are of particular interest in antitumoral therapy due to their dual mechanism of action as antimitotics and vascular disrupting agents. Cyclohexanediones derivatives have been d ...
Microtubule-targeting agents that bind at the colchicine-site of tubulin are of particular interest in antitumoral therapy due to their dual mechanism of action as antimitotics and vascular disrupting agents. Cyclohexanediones derivatives have been described as a new family of colchicine-domain binders with an association constant to tubulin similar to that of colchicine. Here, the high-resolution structures of tubulin in complex with cyclohexanediones TUB015 and TUB075 were solved by X-ray crystallography. A detailed analysis of the tubulin-TUB075 interaction by means of computational affinity maps allowed the identification of two additional regions at the binding site that were addressed with the design and synthesis of a new series of cyclohexanediones with a distal 2-substituted benzofurane. These new compounds showed potent antiproliferative activity with IC 50 values in the nM range, arrested cell cycle progression at the G 2 /M phase and induced apoptosis at sub μM concentrations. Moreover, they caused the destruction of a preformed vascular network in vitro and inhibited the migration of endothelial cells at non-toxic concentrations. Finally, these compounds displayed high affinity for tubulin as substantiated by a K b value of 2.87 × 10 8 M -1 which, to the best of our knowledge, represents the highest binding constant measured to date for a colchicine-domain ligand.
Rega Institute for Medical Research, KU Leuven, Herestraat 49, B-3000, Leuven, Belgium.,Department of Biomedical Sciences (Unidad Asociada IQM,CSIC) and Instituto de Investigación Quimica "Andrés M. del Río" (IQAR), University of Alcalá, Unidad Asociada CSIC, 28805 Alcalá de Henares, Madrid, Spain.,University of Basel, Biozentrum, CH-4056, Basel, Switzerland.,Centro de Investigaciones Biológicas (CIB,CSIC), Ramiro de Maeztu 9, 28040, Madrid, Spain.,Laboratory of Biomolecular Research, Division of Biology and Chemistry, Paul Scherrer Institut, 5232, Villigen, Switzerland.,Instituto de Química Médica (IQM,CSIC), Juan de la Cierva 3, 28006, Madrid, Spain. firstname.lastname@example.org.,Instituto de Química Médica (IQM,CSIC), Juan de la Cierva 3, 28006, Madrid, Spain.